Erasca is a clinical-stage biotechnology company specializing in the development of precision oncology therapeutics for RAS/MAPK pathway-driven cancers. The company leverages a robust pipeline of targeted drug candidates and deep expertise in molecular oncology to address significant unmet medical needs. With a focused strategy on innovative cancer therapies, Erasca aims to establish a competitive edge in the rapidly evolving oncology market.Its Primary customers are anticipated to be healthcare providers, ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (Exact name of Registrant as specified in its Charter) | Delaware | 83-1217027 | | --- | --- | | (State or other j ...

Exhibit 99.1 Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, ...

Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN DIEGO, March ...

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015’s promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-drive ...

Group 1: uniQure - uniQure upgraded to $35 by RBC and $60 by Wells Fargo, currently trading at $16.52, with a 53.33% increase over the past week [1] - The departure of Vinay Prasad from the FDA is viewed positively, with RBC assigning a 50% chance of drug approval for Huntington's disease [1] - Clinical data shows a 75% slowing in disease progression on cUHDRS and 60% on TFC, with a planned Type B meeting with the FDA in Q2 2026 [1] Group 2: Syndax - Syndax's price target raised to $45 from $33 by JPMorgan, currently trading at $23.23, with a consensus target of $38.09 [1] - The company is not currently receiving value for the Niktimvo IPF opportunity, with Phase 2 MAXPIRe data expected in Q4 2026 [1] - Q4 revenue for Revuforj was $44.20 million, up 38% sequentially, with management guiding toward profitability without additional capital raises [1] Group 3: Erasca - Erasca added to JPMorgan's "Positive Catalyst Watch list" ahead of the Phase 1 AURORAS-1 readout for ERAS-0015, expected in the first half of 2026 [1] - The firm sees potential share upside into the high-teens to high-$20s, with a year-end 2026 price target of $24 [1] - Erasca currently trades at $15.20, up 305.17% year-to-date, with a consensus target of $11.56 [1]

Key Takeaways TNGX shares surged 36.3% to a record high after ERAS announced a clinical trial collaboration and supply deal.ERAS will supply ERAS-0015 while TNGX sponsors a phase I/II combo study in MTAP-deleted RAS-mutant cancers.TNGX plans to initiate a pivotal study of vopimetostat monotherapy in MTAP-deleted pancreatic cancer in 2026.Shares of Tango Therapeutics (TNGX) surged 36.3% on Thursday to a record high after Erasca (ERAS) announced a clinical trial collaboration and supply agreement with the com ...

Core Insights - Erasca, Inc. has announced a clinical trial collaboration with Tango Therapeutics to evaluate ERAS-0015, a pan-RAS molecular glue, in combination with Tango's PRMT5 inhibitor, vopimetostat [1][2] Group 1: Clinical Trial Collaboration - The collaboration involves a Phase 1/2 clinical trial targeting patients with MTAP-deleted pancreatic cancer or MTAP-deleted RAS-mutant non-small cell lung cancer (NSCLC) [2][3] - Erasca will supply ERAS-0015 at no cost, while Tango will act as the trial sponsor [1][2] Group 2: Product Details - ERAS-0015 is designed to inhibit RAS signaling and has shown early clinical activity at a dose of 8 mg once daily, with confirmed and unconfirmed responses across multiple tumor types [4] - Preclinical studies indicate that ERAS-0015 has 8-21 times higher binding affinity to cyclophilin A compared to RMC-6236 and demonstrates approximately 5 times greater potency in RAS inhibition [4] Group 3: Market Opportunity - Nearly all MTAP-deleted pancreatic cancers and 30% of MTAP-deleted NSCLC tumors have co-occurring RAS mutations, indicating a significant market need for effective treatments targeting these cancers [3] - The combination of ERAS-0015 and vopimetostat may provide a dual-targeted approach to enhance treatment efficacy and reduce resistance in difficult-to-treat cancers [3]

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the potential of AI to unlock multi-trillion-dollar opportunities, reinforcing the optimistic outlook on AI's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is seen as a catalyst for redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting that it could be a significant investment opportunity [4][6] - Prominent figures in technology and finance, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8]